steri strong steril growth product
backlog bode fine finish
page full analyst note feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
headquart ireland domin forc medic
devic steril steril one third medic devic
world offer full suit steril solut
sale individu steril full outsourc
benefit regardless hospit choos manag steril
also strong presenc oper room
approxim share oper room capit equip
includ surgic tabl light
appli steril technolog segment
increas area focu compani given unit nearli
margin sound competit posit high
up-front cost large-scal devic steril
make difficult competitor ramp product give
advantag establish player make invest
keep grow demand commit
signific dollar expans ast attempt win
busi main competitor sterigen invest
often good use capit newer plant ramp
gener return cost capit five-year period steri
abil select expand plant footprint import
determin return sinc expand quickli could result
underutil plant compress margin busi
though acquisit activ mute recent year
purchas us endoscopi merger synergi
signific compani opinion
transact well execut believ merger
synergi help bolster moat posit compani
growth initi fall margin recov close
premerg level indic combin entiti abl
find synergi merger also allow redomicil
ireland give compani downsid protect event
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
 -base medic devic compani focus steril
servic infect prevent compani global leader
contract steril servic ensur safe deliveri single-us
implant medic equip hospit around world addit
sell steril washer-disinfector decontamin
equip suppli use care provid facil biopharma
manufactur site domicil unit state
invers firm continu deriv roughli revenu
oper unit kingdom remain
intern region
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
steri strong steril growth product
backlog bode fine finish feb
narrow-moat continu string strong quarter
fiscal third quarter margin exceed sale
growth margin estim leav fair
valu estim place long-term view
compani unchang share result
like push name territori
make stock fairli valu view
earn call manag cite time project
push higher capit spend primarili
steril capac growth fiscal
think best interest acceler
expenditur meet capac demand
watch higher capit spend come quarter
plan updat model account new
guidanc follow end fiscal year
year-over-year revenu growth post
best growth quarter three year think fiscal year
sale growth get close line manag
updat guidanc expect could
difficulti maintain above-trend growth longer
term still forecast sale growth high singl
digit come two three year driven growth
healthcar specialti appli steril
support consist growth healthcar product
revenu life scienc busi volatil
third-quart year-over-year growth
second quarter suggest full-year result
segment end good spot
oper margin expand sequenti
basi point quarter mainli attribut life
scienc segment sequenti
margin growth pleas see life scienc sale
segment margin rebound tough second
quarter contrast expect healthcar specialti
margin trend downward given start-up cost
busi also thought record margin appli
steril earli fiscal unsustain
near term slightli lower margin segment track
expect
capit expenditur quarter surpris lower
end around sale compar forecast
closer discrep explain
call manag also discuss concern
ethylen oxid eto steril biggest risk steri
near term state local govern prohibit
use eto medic devic steril
concern environment safeti chemic
illinoi consid outright ban ethylen oxid
steril georgia limit eto state
plant eto steril account
total revenu though unexpect regulatori chang
would impact think diversifi enough
withstand near-term shock past year
food drug administr put forth two open
challeng reduc eto use maintain devic suppli
chain compani select
winner challeng receiv fda support
sever project think altern eto still long
way scale commerci viabil like
initi reduc eto usag help
allevi concern state local govern
view abl effect adapt
on-going industri shift toward less frequent safer
peg fair valu estim per share
primari driver increas fair valu estim
lower cost equiti driven view
resili busi model hold well volatil
econom condit weve also increas forecast
slightli account recent result adjust
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
procedur continu increas complex
procedur total joint replac requir
steril expect adjust oper margin
end five-year forecast period
improv although
appli steril technolog segment account
total revenu outsiz contribut
oper incom expect account greater
portion incom time believ expans
segment push oper margin closer
next five year compar current margin near
use weight cost capit reflect
view compani averag systemat
risk equiti credit risk view much
busi immun effect econom downturn
life scienc appli steril technolog
medium level uncertainti stock
valu per share base case
across board invest appli steril
technolog pay compani establish strong
geograph footprint europ asia-pacif
market scenario gross margin expans averag
basi point explicit forecast period
top-lin growth averag healthcar specialti
view upsid scenario involv acceler
hospital-set steril outsourc unit
state adopt model similar system
steril offload third parti agre
manag assert healthcar specialti could
achiev midteen oper margin longer term
margin steadi state bullish
scenario polici chang increas healthcar
estim long-term pipelin project like
hospit autom opioid safetynet
custom littl choic stick
servic even equip purchas postpon
financi belt tighten also believ
pocket busi life scienc
rel unaffect overal market condit
pharmaceut demand particularli tend reli
capit equip life cycl macroeconom
cyclic provid buffer soften
demand appli steril technolog servic
downturn given devic steril requir
oper procedur nonelect patient
healthcar emerg
manag estim core market grow
think lead market posit
provid above-market growth life
scienc rebound year growth
forecast buoy expect greater devic
steril demand number oper room
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
coverag benefit increas
demand devic steril goldilock scenario
would medicar program though
think public option like assum democrat
control govern either way increas number
peopl insur would provid power tailwind
growth also think newer steril plant ramp
high util well within expect three-
five-year time frame oper margin remain
strong despit lower-margin newer
plant come line fair valu estim
price-to-earnings multipl time
upsid scenario correspond
bear case still expect growth continu
rebound coupl below-trend year
long-term growth stabil around healthcar
specialti assum oper margin remain
manag long-term expect midteen
invest appli steril technolog
plant take longer expect bear fruit although
dont expect devic steril busi come
seriou regulatori threat even bear case
greater awar risk relat ethylen oxid
steril demand altern could result
mute growth scenario would expect appli
steril technolog segment growth remain
growth rate achiev earli fiscal
competit space could offer custom new option
bearish scenario gross margin effect stabl
five-year forecast adjust oper
margin experienc mute growth basi point
period fair valu estim
downsid scenario correspond price-to-earnings
multipl time
think narrow econom moat
busi benefit high switch cost revenu
sticki cost advantag steril technolog
view appli steril technolog segment
wide-moat busi strength partial off-set
lower-margin no-moat healthcar specialti
segment also think healthcar product life
scienc segment narrow moat confid
continu earn excess return next
year recur revenu model use
switch cost provid buffer
cyclic natur capit equip mani steri
product washer steril design
specif medic devic reliabl key concern
custom high cost aris
reprocess fail custom littl incent switch
anoth equip supplier cost
retrain healthcar worker reluct
chang process that work effect view
sustain busi model compani
pois maintain competit advantag
healthcar product bread butter
busi total sale think segment
benefit switch cost underpin narrow moat
infect prevent capit servic side
equip like steril washer sold custom
lock use routin servic
consum life product model
variant razor-and-blad busi model common
medic devic industri higher-cost capit
equip sold low margin greater profit
earn recur consum servic life
scienc segment revenu similar busi
model compani gener revenu
clean chemistri capit
equip steril washer servic
equip life scienc sale growth capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equip tend cyclic custom
replac wave typic usag period end
firm remain major competitor durabl equip
oper tabl dont believ
moat busi competitor easili
replic product
segment wide-moat busi medic devic
touch human need steril primarili done
two method ga radiat small
percentag steril use steam acid steri
process one third medic devic global
primari competitor sterigen also process one third
global medic devic larger devic maker account
rest
medic devic steril tend rel low-cost
compon overal cost healthcar price
compar cost transport devic
off-sit steril crucial medic
footprint offer cost-effici servic limit
turnaround time devic reprocess
use accord survey conduct associ
charg per hour minimum charg
per hour maximum nearli
translat wait cost hour
devic unavail steril hospit
like choos steril provid provid
quickest turnaround time pass-through
ship handl cost reduc time cost
devic unavail
believ cost advantag oper
steril plant larg scale compani
low per-unit cost steril help
benefit strong switch cost around
custom contract last three five year retent
high manufactur regulatori approv
devic steril specif steril
chamber therefor switch anoth provid isnt
practic possibl near term sinc pass-through
ship handl exceed steril cost
lower-pr provid could still expens
locat farther away establish
trustworthi steril provid also benefit
trace intang asset hospit ill afford use
devic havent effect steril
rel low cost steril compar overal
devic cost limit chanc custom would risk
switch anoth provid also trace
effici scale moat sourc there
incent steril provid directli compet
geograph area sinc would result plant
low util rate lead margin compress
dont think enjoy moat healthcar specialti
two third revenu segment come
commodit repair surgic instrument see
potenti moat remain third segment
includ endoscop reprocess steril
outsourc merger synergi health
largest provid steril outsourc
 compani oper like
moat long-term contract britain
nation health servic strength busi
doesnt fulli off-set commodit surgic repair
busi also dont believ oper room capit
equip busi moat stand-alon basi
enter procedur capit busi less
year ago one largest player
indic potenti competit replic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
greater outsourc long term current
steril process like remain place
think moat trend stabl dont see evid
strength compani moat
segment chang next half decad
expect competit posit remain intact
come year
believ appli steril technolog segment
stabl trend could revisit rate see
evid improv switch cost lengthier
contract
competit posit rel closest competitor
sterigen improv compani abl
captur share closur two sterigen
steril plant illinoi georgia concern
relat carcinogen impact steril
process howev abil capit take
busi limit capac sinc facil typic run
capac level high low rang
view healthcar product life scienc
segment stabl trend segment benefit
razor-and-blad model gener consist
sale consum servic foothold
establish capit equip well establish
space dont see immedi risk
busi model also dont see opportun
improv monet otherwis strengthen
moat segment next half decad
account two third segment revenu think
outsourc compon could eventu see
strengthen switch cost steril outsourc
becom increasingli popular hospit system
think full outsourc could moati oper
preval long-term contract howev shift
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oinvestor concern potenti ethylen oxid
regul overblown regul wont allow
medic devic shortag occur
adapt chang longer term
benefit greater surgeri demand
age babi boomer requir increasingli
oan emphasi healthi life expect could increas
preval joint replac earlier life
subsequ repair replac drive
demand devic steril
oth proport surgeri consid minim
invas increas less-invas procedur
odespit compani chang domicil ireland
continu uncertainti withdraw process
caus friction eurozon
brexit revers compani expens
move could prove wast
ogeting sterigen eventu rebound
recent struggl increas competit pressur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
think excel financi strength apart
leverag remain low time
debt/ebitda higher leverag time
attribut merger -base
synergi fiscal year-end leverag
time debt/adjust ebitda manag said
lender believ optim capit structur
time time debt/ebitda dont expect
compani come near lower end rang
forecast period expect interest coverag ratio
remain high interest coverag adjust debt/ebitda
fell low still quit healthi current
hover around time anticip coverag ratio
remain doubl digit forese futur
indic ampl financi strength servic
debt despit capit expenditur routin exceed
industri averag often excess sale
compani abl gener high level free cash
flow excess million past three
year even capit spend expect tick upward
current fiscal year abl
gener cash flow close million come
year think reason assum cash flow
gener could expand beyond come year
also priorit grow dividend averag
dividend growth last five year per
shouldnt difficulti alloc capit
medium level uncertainti stock
medic devic need steril regardless econom
condit even equip sale dip
econom downturn expect overal growth
remain rel stabl support less cyclic
sever
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
contract lower demand healthcar would
impact revenu growth could wane steri could take
hit medic excis tax set come
effect januari previou period
taxat paid million annual
anticip tax would neg impact
million million per year recent
concern around ethylen oxid eto steril there
risk regul could ban limit use eto
account half devic steril
near term municip state could enact ban eto
steril like one current consider
illinoi howev sinc could medic devic
shortag addit plant close believ
regul would act necessari ensur medic devic
avail unlik widespread ban eto would
implement altern solut found
industri expert believ shift away eto would requir
transit period least five year there
remot possibl full ban eto plant think
would prepar transit altern
financi posit
expertis steri also face addit risk regul
delay product approv late
forc discontinu sale system
approv process concern food drug
administr issu like occur would
materi impact busi
strong
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
award standard stewardship rate
believ compani leader effect steward
sharehold capit board member
independ ceo walter rosebrough
except like compani elect board
signific percentag
rosebrough remuner highli variabl account
total compens compani use
ebit
determin execut
compens like inclus free cash flow
pay metric relev sharehold return
fiscal fix salari account averag
total compens name execut offic
believ execut compens reason line
market
also like manag demonstr
willing invest busi margin exce
certain long-term target compani look invest
opportun -- appli steril technolog plant
expans higher research spend -- rather tri
maxim short-term profit us indic
keep eye futur enhanc
long-term viabil busi use return
invest capit primari metric analyz busi
decis give manag credit consid
roic financi plan process align well
view roic effect indic
repurchas million share expect
annual repurchas similar scale forecast
period believ repurchas effect use
capit given free cash flow busi
exceed million last three year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
steril sovereign transfer
coverag fair valu estim dec
relaunch cover increas
valu estim maintain
narrow moat rate weve reduc cost equiti
take fresh look busi use
weight cost capit reflect view steri
benefit below-averag systemat risk equiti
weve also made slight upward adjust model
account strong growth first half
fiscal year refresh view plant invest
contract steril bear fruit help firm
maintain top spot industri
narrow moat moor consider switch
cost custom littl choic stick
equip servic even capit spend
pocket busi
pharmaceut rel unaffect overal market
condit zig area zag gener
lower cyclic risk compani would also expect
demand contract steril stay growth-posit
downturn given devic steril requir
oper procedur often nonelect
patient healthcar emerg
moat perspect contract steril appli
steril technolog interest
moatworthi segment one largest steril
plant footprint provid reliabl time
steril largest medic devic manufactur
signific cost advantag smaller player
strong posit sustain steril contract
often run three five year longer tend
high custom retent stand-alon basi
believ segment wide moat busi
post robust oper margin profil excess
share trade rang think discount
fair valu partial explain on-going
concern possibl regul ethylen oxid
steril sever competitor plant close
past year health concern use
ga steril process there remot
possibl full shutdown ethylen oxid steril
plant dont see like scenario
believ administr regul would act
necessari ensur medic devic avail
model widespread regul chang even bear
case note industri expert believ shift away
ethylen oxid would requir transit period
least five year
demonstr
consist grow revenu market rate
weve pencil growth explicit
forecast period expect buoy medic
devic steril growth increas preval
complex medic procedur tend requir
medic devic lead greater anteced devic
note expect healthcar demand would
lack without mention potenti impact
medicar polici though assign less
chanc medicar polici chang increas
healthcar coverag benefit
greater demand devic steril peopl
get coverag first time opt procedur
might otherwis forgo think medicar public
administr increas number insur
peopl would power tailwind could drive top-
line growth doubl digit
far
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
drop coverag sep
drop coverag provid broad
coverag compani global
period adjust coverag accord investor
interest staf expect reiniti coverag
next quarter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end march
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end march
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
